Used in the treatment of moderate to severe asthma, particularly in patients with elevated type 2 inflammation markers such as eosinophils or fractional exhaled nitric oxide (FeNO). It targets and neutralizes interleukin-13 (IL-17), a key cytokine involved in airway inflammation, mucus production, and airway hyperresponsiveness. By blocking IL-13, it helps reduce asthma exacerbations, improve lung function, and decrease reliance on oral corticosteroids. Also under investigation for use in other IL-13-mediated conditions like atopic dermatitis and chronic rhinosinusitis with nasal polyps. Administered via subcutaneous injection, it offers a targeted biologic therapy option for patients uncontrolled on standard treatments.